open access

Vol 15, No 1 (2019)
Case report
Published online: 2019-04-16
Get Citation

Nivolumab in treatment of renal cell carcinoma during renal replacement therapy

Kamil Konopka
DOI: 10.5603/OCP.2018.0039
·
Oncol Clin Pract 2019;15(1).

open access

Vol 15, No 1 (2019)
CASE REPORT
Published online: 2019-04-16

Abstract

The prolongation of overall survival of advanced RCC patients requires the use of modern therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors. Although these drugs have different pharmacokinetics, preclinical studies rarely indicate significant renal clearance. To date there has been a lack of prospective studies evaluating their efficacy and safety in end-stage renal disease patients undergoing dialysis. This case study describes second-line treatment of RCC with nivolumab in a dialysed patient following bilateral nephrectomy.

Abstract

The prolongation of overall survival of advanced RCC patients requires the use of modern therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors. Although these drugs have different pharmacokinetics, preclinical studies rarely indicate significant renal clearance. To date there has been a lack of prospective studies evaluating their efficacy and safety in end-stage renal disease patients undergoing dialysis. This case study describes second-line treatment of RCC with nivolumab in a dialysed patient following bilateral nephrectomy.

Get Citation

Keywords

kidney cancer, nivolumab, dialysis

About this article
Title

Nivolumab in treatment of renal cell carcinoma during renal replacement therapy

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 1 (2019)

Article type

Case report

Published online

2019-04-16

DOI

10.5603/OCP.2018.0039

Bibliographic record

Oncol Clin Pract 2019;15(1).

Keywords

kidney cancer
nivolumab
dialysis

Authors

Kamil Konopka

References (3)
  1. Markić D, Valencić M, Spanjol J, et al. Renal function outcomes after nephrectomy for kidney cancer in elderly patients. Coll Antropol. 2011; 35 Suppl 2: 121–124.
  2. Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  3. Bajaj G, Wang X, Agrawal S, et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017; 6(1): 58–66.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl